CUPERTINO, Calif., June 26, 2020 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that Gilead Sciences, Inc., (Gilead) has provided notice that, effective as of December 22, 2020, it is terminating the License Agreement dated July 19, 2019 and a related R&D agreement between Gilead and DURECT related to the development and commercialization of a […]
CUPERTINO, Calif., May 28, 2020 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown, President and CEO, will be presenting at the Jefferies 2020 Virtual Health Care Conference, Wednesday, June 3, 2020 at 10:00 a.m. EDT / 7:00 a.m. PDT. Institutional investors and analysts that are participating in the conference may request a
DURECT to Present at the Jefferies 2020 Virtual Health Care Conference Read More »
— Improvements in both serum liver enzymes and liver imaging — Improvement in serum lipid profile — DUR-928 was well tolerated with no significant adverse events — Promising data support further development of DUR-928 in NASH CUPERTINO, Calif., May 26, 2020 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced positive topline results from its Phase 1b
Working on Proof-of-Concept Phase 2 Trial in COVID-19 Patients with Acute Liver or Kidney Injury Live Webcast of Earnings Call Today, May 11th at 4:30 p.m. ET CUPERTINO, Calif., May 11, 2020 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended March 31, 2020 and provided a corporate update.
DURECT Corporation Announces First Quarter 2020 Financial Results and Update of Programs Read More »
CUPERTINO, Calif., May 4, 2020 DURECT Corporation (Nasdaq: DRRX) today announced that it will report first quarter 2020 financial results and host a conference call after the market close on Monday, May 11, 2020. Monday May 11th @ 4:30pm Eastern Time/ 1:30 p.m. Pacific Time Toll Free: 877-407-0784 International: 201-689-8560 Conference ID: 13703442 Webcast: http://public.viavid.com/index.php?id=139763 About DURECT Corporation
Fourth Quarter Highlighted by Presentation of Positive DUR-928 Phase 2a Alcoholic Hepatitis Data at the Liver Meeting® 2019 Live Webcast of Earnings Call Today at 4:30 p.m. Eastern Time CUPERTINO, Calif., March 3, 2020 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months and year ended December 31, 2019 and
CUPERTINO, Calif., Feb. 26, 2020 /PRNewswire / — DURECT Corporation (Nasdaq: DRRX) today announced that it will report its fourth quarter and year ended December 31, 2019 financial results and host a conference call after the market close on Tuesday, March 3, 2020. Tuesday March 3rd @ 4:30pmET/1:30 p.m. Pacific Time Toll Free: 877-407-0784 International: 201-689-8560
DURECT Corporation to Announce 2019 Financial Results on March 3 Read More »
CUPERTINO, Calif., Jan. 17, 2020 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that the U.S. Food and Drug Administration’s (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) met yesterday to discuss the Class 2 New Drug Application (NDA) resubmission for POSIMIR® (bupivacaine extended-release solution). In a split vote on the key question, six
DURECT Corporation Announces Outcome of FDA Advisory Committee Meeting for POSIMIR® Read More »
CUPERTINO, Calif., Jan. 16, 2020 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that NASDAQ has halted trading of the Company’s common stock today. The U.S. Food and Drug Administration’s (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) is holding a meeting today from 8 a.m. to 5 p.m. ET to discuss POSIMIR, an investigational
CUPERTINO, Calif., Jan. 2, 2020 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced the results from its Phase 2a clinical trial of DUR-928 in patients with mild to moderate plaque psoriasis. Twenty-two patients completed the study, applying DUR-928 topically to the plaque on one arm and the vehicle (placebo) to a similar plaque on the other arm
